tirzepatide for the treatment of obstructive sleep apnea Eli Lilly's gained FDA approval in December 2024 treating moderate-to-severe in adults with obesity, after Phase III trials showed a 20% average weight loss and a roughly ZEPBOUND (Tirzepatide) FDA-Approved for Obstructive

The most common side effects reported are gastrointestinal in nature, including: Nausea Vomiting Diarrhea Constipation These side effects tend to be mild to moderate and typically decrease over time as your body adjusts to the medication

Do not attempt to re-inject or double-dose without medical advice

Health Status and Medical History Before taking injections for medical weight loss, its vital to undergo a comprehensive evaluation of ones health status and medical history, as patients with certain conditions may not be good candidates for this weight loss method

Compounding continues under specific medical-need exemptions: customized doses, formulations with B12 or other additives, and allergen considerations

10.1038/379069a0 121 VahlT

While physicians have the legal authority to prescribe medications off-label when they believe it is in the patient's best interest, such use carries additional responsibilities for informed consent and monitoring